Targeted drug delivery is a safe, proven, and effective way to manage chronic pain with fewer side effects and lower doses than oral medication.1
See how Medtronic Targeted Drug Delivery helps you manage chronic pain.
Targeted drug delivery provides effective pain relief by delivering medication directly to the fluid surrounding the spinal cord via a programmable pump.1,2
SynchroMed™ II Pump: A programmable pump that accurately delivers medicine per the dosing instructions provided by your physician.
Ascenda Catheter: A thin, flexible tube that connects to the pump and delivers medication.
Clinician Programmer: A physician uses the tablet to tailor the therapy to best meet your needs.
myPTM Personal Therapy Manager: This handheld device prescribed by your physician at time of implant helps you manage unpredictable pain. The myPTM allows you to receive an extra dose of pain medication when needed and within physician set limits.
A trial allows you to try targeted drug delivery before you commit to an implant.
During the surgery, the SynchroMed II pump is implanted just under the skin of the abdomen.
At follow up appointments, your physician fills the pump with pain medication. The pump sends the medication through the catheter to the spinal area where pain receptors are located. You return to your physician’s office for more medicine when the pump needs to be refilled.
Surgical complications are possible. Some of these complications may include infection, headache, spinal fluid leak, or paralysis.
Do not have the implant surgery if you have an active infection at the time, or if your body size is too small to hold the drug pump.
Once the device is implanted, device complications or adverse drug events may occur, which could be life threatening or require additional surgery to resolve.
Please see Important Safety Information for more details. Also, please discuss the benefits and risks of this therapy with your physician.
Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304-1313.
Deer T, Chapple I, Classen A, et al. lntrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. Pain Med. 2004;5:6-13.
Roberts LJ, Finch PM, Goucke CR, Price LM. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001;5:353-361.
Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncot. 2002;20:4040-4049.
Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.